Zymeworks Inc.

ZYME

US98985Y1082

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:18:04 30/04/2024 BST			5-day change	1st Jan Change
8.47 ^USD	+1.68%		-0.58%	-18.09%

04-08	Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	CI
04-04	Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	CI

Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer

January 04, 2023 at 09:21 pm

On January 3, 2023, Zymeworks Inc. removed Dr. Neil Josephson from the position of Chief Medical Officer, effective immediately.

Latest news about Zymeworks Inc.

Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	04-08	CI
Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	04-04	CI
Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President	04-04	CI
Zymeworks Inc. Announces the Composition of the Committees	03-28	CI
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024	03-28	CI
Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating	03-12	MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	03-11	MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Transcript : Zymeworks Inc., Q4 2023 Earnings Call, Mar 06, 2024	03-06
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-06	CI
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	03-05	CI
Zymeworks Inc. Appoints Scott Platshon as Director	02-22	CI
Transcript : Zymeworks Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-22-2024 08:00 AM	02-22
Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors	02-08	CI
Transcript : Zymeworks Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM	01-11
Zymeworks Insider Sold Shares Worth $257,845, According to a Recent SEC Filing	01-09	MT
Zymeworks Appoints Jeffrey Smith as Chief Medical Officer; Cash Runway Extended	01-04	MT
Zymeworks Inc Announces Additional Leadership Appointments	01-04	CI
Zymeworks Reports $50 Million Private Placement to EcoR1 Capital	12-26	MT
Zymeworks Inc. announced that it expects to receive $49.999993 million in funding from EcoR1 Capital, LLC	12-22	CI
Zymeworks Inc.(NasdaqGS:ZYME) added to NASDAQ Biotechnology Index	12-18	CI
Zymeworks Expects to Be Added to Nasdaq Biotech Index	12-15	MT
Zymeworks Inc. Announces Changes to its Board	12-08	CI
Transcript : Zymeworks Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Sector

Biotechnology & Medical Research

Calendar

01/05/2024 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Zymeworks Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.33 USD

Average target price

14.17 USD

Spread / Average Target

+70.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZYMEWORKS INC.	-18.09%	588M
VERTEX PHARMACEUTICALS INCORPORATED	-3.13%	102B
REGENERON PHARMACEUTICALS, INC.	+1.90%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.63%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-14.70%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	13.97B
SAREPTA THERAPEUTICS, INC.	+32.95%	12.17B

Bio Therapeutic Drugs

Zymeworks Inc.

Equities

ZYME

US98985Y1082

Biotechnology & Medical Research

Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer

Latest news about Zymeworks Inc.

Chart Zymeworks Inc.

Company Profile

Income Statement Evolution

Ratings for Zymeworks Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs